Cell-mediated targeting of toxins to pathogenic cells

Details Cell-mediated targeting of toxins to pathogenic cells Cell-mediated targeting of toxins to pathogenic cells

2006-09-05

2006-09-05

Li, Q. Janice (Department: 1632)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S093100, C424S093200, C435S069100, C435S320100, C435S455000, C514S04400A

Reexamination Certificate

active

07101542

ABSTRACT:
The invention features vectors encoding immunotoxic fusion proteins containing targeting domains and toxic domains, targeting cells transduced with the vectors, methods of making the targeting cells, and methods of treating diseases (e.g., cancer) using both the vectors and the transduced cells.

REFERENCES:
patent: 5736387 (1998-04-01), Paul et al.
patent: 6001329 (1999-12-01), Buchsbaum et al.
patent: WO 98/17116 (1998-04-01), None
Verma et al., Gene therapy-promises, problems and prospects, 1997,NATURE, vol. 389, pp. 239-242.
Deonarain, Ligand-targeted receptor-mediated vectors for gene delivery, 1998, Exp. Opin. Ther. Patents, vol. 8, pp. 53-69.
Crystal, Transfer of genes to humans: early lessons and obstacles to success, 1995, SCIENCE, vol. 270, pp. 404-410.
Miller et al., Targeted vectors for gene therapy, 1995, FASEB, pp. 190-199.
Cochlovius et al, Cancer Immunol Immunother 1998;46:61-6.
Debinski et al, J Bio Chem 1993;268:14065-70.
Clay et al, Pathol Oncol Res Jan. 1999;5:3-15.
Kreitman et al, Int J Immunopharm 1992;14:465-72.
Moreck et al, Cancer Immunol Immunother,1991;32:342-352.
Heslop et al, Curr Opin Hematol 1995;2:417-22.
Sweeney et al, Bioconj Chem 1998;9:201-7.
Boyer et al., “The Role of B7 Costimulation by Murine Acute Myeloid Leukemia in the Generation and Function of a CD8+ T-Cell Line With Potent In Vivo Graft-Versus-Leukemia Properties,” Blood 89(9):3477-3485, 1997.
Chung-Huang Chan et al., “Reactivity of Murine Cytokine Fusion Toxin, Diphtheria Toxin390-Murine Interleukin-3 (DT390-mIL-3), with Bone Marrow Progenitor Cells,” Blood 88(4):1445-1456, 1996.
Chung-Huang Chan et al., “A Murine Cytokine Fusion Toxin Specifically Targeting the Murine Granulocyte-Macrophage Colony-Stimulating Factor . . . Receptor on Normal Committed Bone Marrow Progenitor Cells and GM-CSF-Dependent Tumor Cells,” Blood 86(7):2732-2740, 1995.
Si-Yi Chen, “A Novel Artificial Tumor-Specific Killer Cell and Intrabody Approaches for Cancer Therapy,” Chapter 25, pp. 389-396, InGene Therapy of Cancer, Academic Press, 1999.
Si-Yi Chen et al., “Potent antitumour activity of a new class of tumour-specific killer cells,” Nature 385:78-80, 1997.
An-Gan Yang et al., “A new class of antigen-specific killer cells,” Nature Biotechnology 15:46-51, 1997.

Affiliated with

Also associated with

Rating

Cell-mediated targeting of toxins to pathogenic cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cell-mediated targeting of toxins to pathogenic cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell-mediated targeting of toxins to pathogenic cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3542575